For research and development scientists in the pharmaceutical sector, the selection of appropriate chemical intermediates can dramatically influence the success of a project. 2-(2-Bromoethyl)-1,3-dioxane (CAS 33884-43-4) is a prime example of such a critical compound, widely used for its versatile reactivity and structural benefits in complex organic syntheses.

Chemical Profile and Reactivity

The molecular formula for this intermediate is C6H11BrO2, with a molecular weight of 195.05 g/mol. Its structure features a dioxane ring protecting a bromoethyl group. This masked aldehyde functionality is particularly valuable. In Grignard reactions, the bromoethyl portion readily reacts, allowing for the controlled addition of a two-carbon chain with a protected aldehyde. This controlled reactivity is crucial for researchers aiming to build specific molecular architectures for drug candidates.

The stability of the dioxane ring under acidic conditions and the thermal stability of its Grignard derivative offer significant advantages in multi-step syntheses. This predictability allows scientists to plan and execute reactions with greater confidence, minimizing side reactions and maximizing the yield of the desired product. Researchers often look to buy this compound from reputable manufacturers who can provide documentation on its purity and stability.

Applications in Drug Discovery and Development

The primary application of 2-(2-Bromoethyl)-1,3-dioxane lies in its role as a pharmaceutical intermediate. It serves as a precursor for a wide array of bioactive molecules. For instance, its derivatives can be found in compounds targeting specific cellular pathways or disease mechanisms. Its utility extends to the synthesis of various heterocyclic compounds and functionalized chains that are core components of many pharmaceuticals. Scientists aiming to develop novel therapeutics will find this intermediate a valuable tool in their synthetic arsenal.

When considering its purchase, R&D scientists should engage with chemical suppliers who can offer this intermediate with high purity levels, often specified as 99% minimum. Access to detailed technical data and sample quantities can facilitate initial feasibility studies. Building relationships with manufacturers who specialize in pharmaceutical intermediates ensures a reliable supply for ongoing research and pilot studies, supporting the entire drug development lifecycle.